Novel Metastatic Treatment for Metastatic Ocular Melanoma Patients

Looking for treatment options for metastatic ocular melanoma?

IDEAYA BIOSCIENCES is currently enrolling patients in multiple arms for their clinical trials for metastatic ocular melanoma, as well as front line treatments.

Check out their website,  https://www.ideayabio.com/ for information on their enrolling trials.

Additionally, you can learn more about the uveal melanoma specific trials at the links outlined below.

These trial arms are actively recruiting at multiple sites. For the most up to date information, the best route is to contact your uveal melanoma oncologist.

Trial: NCT05907954 – (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Summary: Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma

Search NCT05907954 on clinicaltrials.gov for more information and a location near you.

————————————————————————————————————————

Trial: NCT05987332 – IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Summary: This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator’s choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).

Search NCT05987332 on clinicaltrials.gov for more information and a location near you.

————————————————————————————————————————–

Trial: NCT03947385 – Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/​11 Mutations or PRKC Fusions

Summary: This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors.

Search NCT03947385 on clinicaltrials.gov for more information and a location near you.